A Critical Commentary
The rapid commercialization of regenerative medicine has led to a noticeable surge in unregulated cross-border wellness clinics offering uncharacterized cellular products for degenerative conditions. Recently, a marketing trend has emerged wherein standard Mesenchymal Stromal Cells (MSCs)—often derived from unexpanded or crudely processed umbilical cord matrix (Wharton’s Jelly)—are branded and sold as Multilineage-differentiating Stress-Enduring (MUSE) cells.
While legitimate, highly purified MUSE cells exhibit unique pluripotent-like capabilities and distinct survival advantages, their physiological scarcity makes authentic isolation a high-precision, technologically intensive endeavor. This article deconstructs the biological distinctions between true MUSE cells and standard heterogeneous MSC populations. It highlights the manufacturing, clinical, and regulatory challenges that undermine the claims of cross-border medical spas and warns against the severe safety and legal implications confronting patients who seek these unregulated procedures.
Introduction
The global landscape of direct-to-consumer regenerative medicine is heavily saturated with clinics offering stem cell therapies that outpace current peer-reviewed evidence and regulatory approval. For over a decade, unexpanded or minimally manipulated Mesenchymal Stromal Cells (MSCs), frequently harvested from adipose tissue, bone marrow, or perinatal tissues like Wharton’s Jelly, have served as the foundational product for commercial “stem cell spas” (Mundra et al., 2012). As consumer skepticism about generic MSC therapies grows because of limited rigorous clinical trials, unverified clinical operations are shifting their marketing to highlight cutting-edge scientific discoveries to maintain a premium commercial edge.
A prominent example of this semantic shift is the commercial rebranding of standard heterogeneous MSC products as “MUSE cell therapy” across various unregulated cross-border health clinics. True MUSE cells represent a rare, endogenous subpopulation of stress-tolerant, pluripotent-like stem cells capable of triploblastic differentiation (Kuroda et al., 2010).
However, translating true MUSE cell biology into safe, reproducible, and clinically efficacious therapeutics requires highly sophisticated biopharmaceutical infrastructure. This paper examines the critical biological divergence between authentic MUSE isolation and the crude MSC products distributed by cross-border spas. It highlights the significant safety risks and the lack of clinical accountability in unregulated cellular tourism.
1. BIOLOGICAL DISTINCTIVENESS: TRUE MUSE CELLS VS. HETEROGENEOUS MSCS
To evaluate the validity of cross-border commercial claims, it is necessary to compare the exact biological profiles of authentic MUSE cells with those of the standard mesenchymal stromal populations with which they are routinely conflated.
Pluripotency and Surface Marker Expression
Mesenchymal Stromal Cells are fundamentally multipotent, but, according to traditional biological consensus, restricted to mesodermal lineages, including osteogenic, chondrogenic, and adipogenic differentiation (Mundra et al., 2012). In contrast, true MUSE cells possess pluripotent-like characteristics. First isolated by Mari Dezawa’s research group, MUSE cells are capable of self-renewal and triploblastic differentiation—meaning a single cell can generate functional cell types across all three primary embryonic germ layers (ectoderm, endoderm, and mesoderm) without exhibiting tumorigenic behavior or forming teratomas in vivo (Kuroda et al., 2010; Velasco et al., 2023).
This functional divergence is dictated by a starkly different transcription factor and surface marker profile:
| Parameter / Marker | Standard Heterogeneous MSCs | Authentic MUSE Cells |
| Embryonic Pluripotency Markers | Undetectable or negligible expression (Alanazi et al., 2023). | Robust expression of Nanog, Oct3/4, Sox2, and Rex1 (Alanazi et al., 2023; Alessio et al., 2018) |
| Primary Surface Marker | CD73+, CD90+, CD105+; SSEA-3 negative. | SSEA-3 positive (Stage-Specific Embryonic Antigen-3) (Alessio et al., 2018; Dezawa, 2025) |
| Physiological Abundance | Comprises the bulk of stromal connective tissue isolates. | Severely scarce: 0.01%–0.03% of bone marrow mononuclear fractions; minor fraction in Wharton’s Jelly (Dezawa, 2025) |
| Differentiation Capacity | Multipotent (restricted strictly to mesodermal lineages) (Mundra et al., 2012). | Pluripotent-like (ectodermal, endodermal, and mesodermal lineages) (Velasco et al., 2023) |
The Stress-Endurance Separation Hurdle
The defining characteristic of authentic MUSE cells is their unique capacity to withstand severe environmental and genotoxic stress—a property from which their name is derived (Kuroda et al., 2010). Legitimate isolation protocols leverage this trait by subjecting a heterogeneous mesenchymal harvest to prolonged, extreme cellular duress:
- Proteolytic Stress: Incubating cultures in long-term trypsin solutions (e.g., up to 8 hours for MSCs or 16 hours for fibroblasts) (Kuroda et al., 2010).
- Environmental Stress: Introducing severe hypoxia, nutrient deprivation, and extreme hypothermia (Alanazi et al., 2023).
This severe selective pressure effectively eradicates the fragile, non-MUSE mesenchymal stromal population, leaving behind the resilient cells that express specialized protective factors, such as 14-3-3 proteins and serpins, to inhibit apoptosis (Alanazi et al., 2023). Furthermore, authentic MUSE cells possess an exceptionally efficient DNA damage repair (DDR) system, specifically upregulating non-homologous end joining (NHEJ) enzymatic activity to survive genotoxic insults that drive standard MSCs into rapid senescence or apoptosis (Alessio et al., 2018).
2. THE COMMERCIAL BAIT-AND-SWITCH: REBRANDING WHARTON’S JELLY
Because adult connective mesenchyme consists of such a limited, scarce population of these pluripotent-like precursors, separating them from their differentiated counterparts before they naturally commit to a specific lineage is highly inefficient without advanced laboratory technologies.
Unregulated clinics circumvent this technological barrier not by optimizing isolation, but by altering their marketing vocabulary. The historical trajectory of their advertising strategy reveals a persistent pattern:
[Crude Perinatal/Tissue Harvest]
│
▼
[Branded as “Wharton’s Jelly”] (Initial Wave)
│
▼
[Rebranded as “Mesenchymal Stem Cells”] (Market Saturation Phase)
│
▼
[Rebranded as “MUSE Cell Therapy”] (Current Premium Trend)
In this current marketing wave, crude Wharton’s Jelly homogenates or standard, unseparated MSC expansions are packaged and priced as “MUSE cells.” This semantic upgrade exploits a baseline biological truth: yes, native Wharton’s Jelly and mesenchymal tissues do contain an endogenous fraction of SSEA-3+ MUSE cells (Dezawa, 2025). However, the mere presence of a rare, complex ingredient within a biological starting material does not guarantee its abundance, isolation, or clinical applicability in the final administered product.
When these clinics perform standard industrial cell expansion to increase volume, they do so without maintaining the highly specialized, continuous selective pressures or advanced fluorescence-activated cell sorting (FACS) required to keep the MUSE population intact. Without these deliberate controls, the highly proliferative, dominant fibroblastic and non-MUSE stromal fractions rapidly outgrow and dilute the minute MUSE population to the point of absolute statistical and clinical insignificance (Alanazi et al., 2023).
3. INFRASTRUCTURE DEFICITS AND THERAPEUTIC HAZARDS IN UNREGULATED SPAS
The manufacturing of pluripotent or pluripotent-like cellular medicines requires an entirely different tier of biopharmaceutical sophistication than what is available to cross-border wellness centers. Legitimate clinical trials for verified donor MUSE cell isolates—which are being investigated for acute myocardial infarction, ischemic stroke, and amyotrophic lateral sclerosis (ALS)—are conducted under stringent Current Good Manufacturing Practices (cGMP) by heavily monitored biopharmaceutical companies (Dezawa, 2025).
Unregulated cross-border spas lack the precise infrastructure required to mitigate the inherent biological risks associated with pluripotent-acting entities:
- Uncontrolled In Vivo Differentiation: Because true MUSE cells can differentiate into any of the three primary germ layers, their therapeutic application requires highly precise coordination (Velasco et al., 2023). If an uncharacterized cell line lacking strict signaling controls and rigorous batch validation is injected systematically or locally into an actively degenerating environment, the risk of erratic, non-specific differentiation, localized fibrotic scarring, or inappropriate tissue formation is dangerously high.
- Contamination and Advanced Quality Control: Culturing cells with high stress-endurance requires sophisticated environmental monitoring to prevent cellular senescence, genomic instability, or endotoxin contamination. Cross-border spas operate outside verifiable, peer-reviewed frameworks and lack the objective, biomarker-driven workflows necessary to demonstrate product purity, viability, or specific batch identity.
CONCLUSION: THE REALITY OF CELLULAR TOURISM
To date, there is zero documented, peer-reviewed clinical evidence demonstrating that the so-called “MUSE cells” administered by unregulated cross-border spas exert any therapeutic impact on degenerative diseases. The clinical reality remains clear: when an uncharacterized, mislabeled, and unregulated biological product is administered without rigorous medical oversight or legal transparency, the provider risks very little. Ultimately, no one other than the patient has anything to lose—biologically, financially, and legally—the moment they step across the regulatory border. Patients should remain highly skeptical and cautious when evaluating vague cellular claims from unverified, non-clinical providers.
— By Surjo Banerjee, Senior Neurobiologist
REFERENCES
Alanazi, R. F., Alhwity, B. S., Almahlawi, R. M., Alatawi, B. D., Albalawi, S. A., Albalawi, R. A., Albalawi, A. A., Abdel-Maksoud, M. S., & Elsherbiny, N. (2023). Multilineage Differentiating Stress Enduring (Muse) Cells: A New Era of Stem Cell-Based Therapy. Cells, 12(13), 1676.
Alessio, N., Squillaro, T., Özcan, S., Di Bernardo, G., Venditti, M., Melone, M., Peluso, G., & Galderisi, U. (2018). Stress and stem cells: adult Muse cells tolerate extensive genotoxic stimuli better than mesenchymal stromal cells. Oncotarget, 9(27), 19328–19341. https://doi.org/10.18632/oncotarget.25039
Dezawa M. (2025). Macrophage- and pluripotent-like reparative Muse cells are unique endogenous stem cells distinct from other somatic stem cells. Frontiers in bioengineering and biotechnology, 13, 1553382.
Kuroda, Y., Kitada, M., Wakao, S., Nishikawa, K., Tanimura, Y., Makinoshima, H., Goda, M., Akashi, H., Inutsuka, A., Niwa, A., Shigemoto, T., Nabeshima, Y., Nakahata, T., Nabeshima, Y., Fujiyoshi, Y., & Dezawa, M. (2010). Unique multipotent cells in adult human mesenchymal cell populations. Proceedings of the National Academy of Sciences of the United States of America, 107(19), 8639–8643. https://doi.org/10.1073/pnas.0911647107
Mundra, V., Gerling, I. C., & Mahato, R. I. (2012). Mesenchymal Stem Cell-Based Therapy. Molecular Pharmaceutics, 10(1), 77-89.
Velasco, M. G., Satué, K., Chicharro, D., Martins, E., Torres-Torrillas, M., Peláez, P., Miguel-Pastor, L., Del Romero, A., Damiá, E., Cuervo, B., Carrillo, J. M., Cugat, R., Sopena, J. J., & Rubio, M. (2023). Multilineage-Differentiating Stress-Enduring Cells (Muse Cells): The Future of Human and Veterinary Regenerative Medicine. Biomedicines, 11(2), 636. https://doi.org/10.3390/biomedicines11020636